In this episode, Erika P. Hamilton, MD, and Komal Jhaveri, MD, discuss their approaches to and key studies for current management of patients with HER2-positive breast cancer. The discussion includes: Optimizing systemic therapy for patients with HER2-positive early breast cancer based on disease characteristics and riskSequencing available therapies for patients with HER2-positive metastatic disease, including new data on first- and second-line therapy and how to manage patients with central nervous system metastasesManaging common adverse events associated with HER2-targeted therapyPresenters:Erika P. Hamilton, MDDirector, Breast and Gynecologic Cancer Research ProgramDrug Development UnitSarah Cannon Research InstituteInvestigatorTennessee OncologyNashville, TennesseeKomal Jhaveri, MDAssistant Professor of MedicineWeill Cornell Medical CollegeAssociate Attending PhysicianBreast Medicine ServiceDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkFollow along with Podcast Pearls slideset:https://bit.ly/3eMqxB8See full program: https://bit.ly/3oBdd45

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related